Literature DB >> 997588

Metabolism of debrisoquine sulphate in rat, dog and man.

J G Allen, A N Brown, T R Marten.   

Abstract

1. The metabolism of debrisoquine sulphate in the dog has been studied and is similar to that in rat and man. 2. Two acidic urinary metabolites, shown to be present in rat, dog and man, have been isolated from rat urine. After derivatization they were characterized by n.m.r. and mass spectroscopy as methyl 2-[2-(4,6-dimethylpyrimidylamino)-methyl]-phenylacetate and 2-[2-(4,6-dimethylpyrimidylamino)-ethyl]benzoate.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 997588     DOI： 10.3109/00498257609151653

Source DB:  PubMed          Journal:  Xenobiotica        ISSN： 0049-8254            Impact factor:   1.908


  10 in total

Review 1.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

2.  Why hypertensive patients vary in their response to oral debrisoquine.

Authors:  J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal:  Br Med J       Date:  1977-02-12

Review 3.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

5.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

6.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

7.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 8.  LC-MS-based metabolomics in drug metabolism.

Authors:  Chi Chen; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

Review 9.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

10.  Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; A Küpfer; E Steiner; C O Meese
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.